Landing strip and surrounding landscape as seen from the approaching plane.

Titratable Control of blood pressure reduction with CLEVIPREX^® (clevidipine)

CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in acute severe hypertension cases. CLEVIPREX is a ready-to-use option and has a ~1-minute half-life.

Cleviprex vials

CLEVIPREX is a low-volume dosing option²

Excessive fluid intake may lead to adverse outcomes in critically ill patients.^3,4 Consider the results of the ECLIPSE trials and see how infusion volumes varied between hypertensive agents in the postoperative setting.

CLEVIPREX has not been studied or proven to impact fluid overload.
Learn more about ECLIPSE and dosing

Dr. Horowitz speaks about CLEVIPREX

Renowned anesthesiologist Dr. Todd Horowitz discusses CLEVIPREX clinical trial results and dosing in a series of informative videos for healthcare professionals.

Renowned anesthesiologist—Dr. Todd Horowitz

Watch videos‍

Proven efficacy in clinical studies

Over 90% of patients with perioperative hypertension achieved treatment success (≥15% BP reduction from baseline within 30 minutes)^5,6
Low rate of overshoot in acute severe hypertension patients in the VELOCITY trial⁷

Explore the clinical studies

BP reduction within minutes²

In perioperative patients, CLEVIPREX produces a 4%–5% reduction in systolic blood pressure (SBP) within 2–4 minutes of initiation
CLEVIPREX has a half-life of ~1 minute. In most patients, full recovery of BP is achieved 5–15 minutes after the infusion is stopped

See the pharmacology data

Demonstrated safety profile

The safety profile of CLEVIPREX was evaluated in multiple clinical trials²

View the trial results

Non–weight-based dosing²

CLEVIPREX offers low-volume, non–weight-based dosing that is independent of renal or hepatic function
Ready-to-use 50 mL and 100 mL vials are available for individualized, titratable administration

Get more info about dosing

Important Safety Information

CLEVIPREX^® (clevidipine) Injectable Emulsion is contraindicated in patients with:

Allergies to soybeans, soy products, eggs, or egg products;
Defective lipid metabolism seen in conditions such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia; and
Severe aortic stenosis.

CLEVIPREX^® is intended for intravenous use. Use aseptic technique and discard any unused product within 12 hours of stopper puncture.

Hypotension and reflex tachycardia are potential consequences of rapid upward titration of CLEVIPREX^®. If either occurs, decrease the dose of CLEVIPREX^®. There is limited experience with short-duration therapy with beta-blockers as a treatment for CLEVIPREX^®-induced tachycardia. Beta-blocker use for this purpose is not recommended.

CLEVIPREX^® contains approximately 0.2 g of lipid per mL (2.0 kcal). Lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism.

Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully.

CLEVIPREX^® is not a beta-blocker, does not reduce heart rate, and gives no protection against the effects of abrupt beta-blocker withdrawal. Beta-blockers should be withdrawn only after a gradual reduction in dose.

Patients who receive prolonged CLEVIPREX^® infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.

There is no information to guide use of CLEVIPREX^® in treating hypertension associated with pheochromocytoma.

Most common adverse reactions for CLEVIPREX^® (>2%) are headache, nausea, and vomiting.

Indication

CLEVIPREX^® (clevidipine) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure (BP) when oral therapy is not feasible or not desirable.

Please see Full Prescribing Information.

References: 1. Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. 2. CLEVIPREX® (clevidipine) Prescribing Information. 2021. 3. Child DL, Cao Z, Seiberlich LE, et al. The costs of fluid overload in the adult intensive care unit: is a small-volume infusion model a proactive solution? Clinicoecon Outcomes Res. 2014;7:1-8. 4. O’Connor ME, Prowle JR. Fluid Overload. Crit Care Clin. 2015;31(4):803-821. 5. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105(4):918-925. 6. Singla N, Warltier DC, Gandhi SD, et al; ESCAPE-2 Study Group. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg. 2008;107(1):59-67. 7. Pollack CV, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Peacock WF. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med. 2009;53(3):329-338.